Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - ... 7 - 8 - 9 - 10 - 11 - 12 - 13 - ...
D'IETEREN [BE0974259880/DIE]   
[18/07/2018]

D'IETEREN : Repurchase of own shares in the context of the liquidity contract

PRESS RELEASE: REPURCHASE OF OWN SHARES IN THE CONTEXT OF THE LIQUIDITY CONTRACT REGULATED INFORMATION Wednesday 18 July 2018 – 6:00 pm CET Repurchase of own shares in the context of... See more
 
UCB [BE0003739530/UCB]   
[13/07/2018]

UCB : UCB Media Room: Transparency Notification

Transparency notificationBrussels Belgium, 13 July 2018 – 20:00 CEST – regulated information1. Summary of the notificationPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification dated 9 July 2018 from BlackRock, Inc. having its registered office at 55 East 52nd Street, New York, NY, 10055,... See more
 
UCB [BE0003739530/UCB]   
[13/07/2018]

UCB : UCB Media Room: BLA Resubmission for Evenity to US FDA

UCB and Amgen Resubmit Biologics Licence Application BLA for EVENITYTM Romosozumab to the U.S. FDABLA Includes Data From Pivotal Phase 3 Studies of More Than 11,000 PatientsBrussels, Belgium and Thousand Oaks, CalifJuly 13, 2018, 07:00 CET – UCB Euronext Brussels: UCB and Amgen NASDAQ:AMGN today announced the resubmission of the Biologics License Application BLA to the U.S. Food and Drug... See more
 
AUDIOVALLEY [BE0974334667/ALAVY]   
[12/07/2018]

AUDIOVALLEY : AudioValley launches its initial public offering ont the Paris Euronext Growth market.

Press release www.audiovalley.com 12 July, 2018 – 08:00 CEST Audiovalley: Sébastien Veldeman  investisseurs@audiovalley.com  Actifin: Alexandre Commerot  acommerot@actifin.fr  AudioValley launches its initial public offering on the Paris Euronext Growth market Capital increase of €9.6 million1 by the issuance of new... See more
 
PHARMASIMPLE [BE0974302342/MLPHA]   
[11/07/2018]

PHARMASIMPLE : Pharmasimple : Chiffre d’affaires du premier semestre 2018. Fortes perspectives de développement.

CHIFFRE D'AFFAIRES DU PREMIER SEMESTRE 2018 FORTES PERSPECTIVES DE DEVELOPPEMENT Bruxelles, Belgique, le 11 juillet 2018, Pharmasimple annonce un chiffre d'affaires en recul à la suite du nonrenouvellement d'un contrat de distribution avec un laboratoire européen. En isolant l'impact de ce contrat spécifique, la croissance du semestre s'établit à 4,1%. Pharmasimple, un...